Skip to content

Identification of Predictors for Coronary Plaque Erosion in Patients With Acute Coronary Syndrome

Identification of Predictors for Coronary Plaque Erosion in Patients With Acute Coronary Syndrome

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03479723
Enrollment
1793
Registered
2018-03-27
Start date
2017-12-01
Completion date
2024-08-01
Last updated
2025-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Brief summary

The purpose of this study is to perform pooled analysis with data collected from 5 previously published studies and 8 unpublished datasets collected from international sites. The main goal of this study is to identify the predictors of plaque erosion.

Detailed description

Plaque erosion is reported to be responsible for about one third of patients with acute coronary syndrome (ACS). In the EROSION study, we reported that antithrombotic therapy without stenting achieved a reduction in thrombus volume greater than 50% in over 70% of patients diagnosed with ACS caused by plaque erosion. This result suggests that the conservative approach of anti-thrombotic therapy without stenting may be an option for patients diagnosed with ACS caused by plaque erosion, which may be the paradigm shift in treatment of ACS patients. However, at present, the only way to make an in vivo diagnosis of plaque erosion is intra-coronary optical coherence tomography (OCT). If we can identify clinical factors associated with plaque erosion, we may be able to narrow down a sub-population of patients with a higher likelihood of plaque erosion. This group of patients may be stabilized with pharmacologic therapy and avoid invasive procedures, thereby preventing related complications and reducing health care burden. However, specific demographic characteristics of the ACS patients with plaque erosion are not known. Our group has the world's largest dataset of patients with plaque erosion and several published reports on plaque erosion. However, the study population of each study is still small and unbalanced to identify the demographic characteristics associated with plaque erosion. Therefore, we propose to pool data from a large number of institutions around the world. This will provide an opportunity to identify factors associated with plaque erosion.

Interventions

None listed

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Diagnosed with ACS upon admission to hospital, including patients with ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina pectoris (UAP). 2. Intra-vascular OCT imaging of culprit vessel.

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
Cardiac death3-year

Secondary

MeasureTime frameDescription
any target lesion revascularization3-yearAny revascularization due to thrombosis or restenosis of the target lesion
all cause death3-year
myocardial infarction3-year
clinically driven target lesion revascularization3-yeartarget lesion revascularization performed because of ischemic symptoms, electrocardiographic changes at rest or positive stress test relists
target-vessel revascularization3-yearRevascularization of any segment of the coronary artery containing the target lesion
any repeat revascularization3-year
stent thrombosis3-yearstent thrombosis was defined according to the Academic Research Consortium criteria
device-oriented composite (cardiac death, target vessel MI, and TLR)3-year
bleeding complication3-yearGusto and BARC definition
patients-oriented composite (all cause death, MI, any repeat coronary revascularization)3-year
target vessel failure (TVF; cardiac death, MI, or ischemia-driven TVR)3-year
major adverse cardiac events (MACEs: cardiac death, MI, or ischemia-driven TLR)3-year
stroke3-year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026